Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated reports developments for a global medical technology business that supplies hospitals and healthcare providers with devices used in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Its established brands include Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck.
Recurring Teleflex news covers quarterly financial results, outlook updates, revenue trends by global product category, portfolio realignment and integration of acquired vascular intervention assets. Company updates also include governance and leadership changes, board committee matters, capital allocation actions, shareholder communications and operational initiatives such as integrated demand and supply planning.
Summary not available.
o9 announced that Teleflex (NYSE: TFX) went live globally on o9's platform for integrated Demand Planning and Supply Planning on March 12, 2026.
This deployment connects demand forecasts and supply plans in one environment, improving cross-functional coordination, inventory and capacity visibility, forecast performance, and alignment on trade-offs across regions and functions.
Teleflex (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share. The dividend is payable March 31, 2026 to shareholders of record at the close of business on March 6, 2026.
Shareholders registered by the record date will receive the March 31 payment; more corporate details are available from the company.
Teleflex (NYSE: TFX) reported full-year 2025 continuing operations GAAP revenue of $1,992.7M (+17.2%) and adjusted revenue of $1,983.7M (+16.3%). Adjusted diluted EPS from continuing operations was $6.98.
Management provided 2026 outlook: GAAP revenue growth 14.4%–15.4%, pro forma adjusted constant currency revenue growth 4.5%–5.5%, and adjusted diluted EPS $6.25–$6.55. Company announced strategic divestitures, expected H2 2026 close, estimated $1.8B after-tax proceeds, and an initial restructuring to mitigate $48M–$52M annual stranded costs.
Teleflex (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 26, 2026.
Participation requires pre-registration to receive dial-in details; the call will be available via live audio webcast on the company website and an audio replay will be available beginning at 11:00 a.m. Eastern Time on February 26, 2026 (conference ID 69028).
Teleflex (NYSE: TFX) appointed Stuart Randle as Interim President and CEO effective immediately and named Dr. Stephen Klasko chairman of the board while the Board engages Spencer Stuart to search for a permanent CEO.
The company provided preliminary full‑year 2025 revenue expectations of $3.270 billion to $3.278 billion, revised from prior guidance of $3.305 billion to $3.320 billion. The reduction reflects softer end‑of‑year demand for intra‑aortic balloon pumps and catheters in the U.S. and Asia, delays in certain OEM purchase orders, and lower order volumes across some portfolio segments. Final fourth quarter and full‑year 2025 results are expected in late February/early March 2026.
Teleflex Medical OEM (to be carved out from Teleflex, NYSE: TFX) will be acquired by Montagu and Kohlberg for $1.5 billion. The carve-out creates an independent contract developer and manufacturer serving structural heart, neurovascular, electrophysiology and urology, with seven facilities across the U.S., Mexico and Ireland.
Closing is expected in second half of 2026, subject to customary regulatory approvals and closing conditions. Greg Stotts will become CEO and Matt Jennings will assume the role of Chairman on closing.
Teleflex (NYSE: TFX) management will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 10:00 a.m. GMT.
A live audio webcast of the presentation will be available on Teleflex's investor website at teleflex.com.
Teleflex (NYSE: TFX) declared a quarterly cash dividend of $0.34 per share. The dividend is payable on December 15, 2025 to shareholders of record at the close of business on November 14, 2025.
This announcement sets the payment and record dates for the next quarterly distribution to common shareholders.
Teleflex (NYSE: TFX) reported third-quarter 2025 results: GAAP revenue $913.0M (+19.4% YoY) and adjusted revenue $892.9M (+16.8% YoY). GAAP diluted EPS from continuing operations was $(9.24) versus $2.36 prior year; adjusted diluted EPS was $3.67 versus $3.49 prior year. The company narrowed full-year 2025 GAAP revenue growth guidance to 9.10%–9.60%, lowered adjusted constant currency revenue growth to 6.90%–7.40%, cut GAAP EPS guidance to $(4.42)–$(4.22) and narrowed adjusted EPS to $14.00–$14.20.
Notable items: $403.9M goodwill impairment (Interventional Urology), $100M Titan SGS impairment, total impairments ~$512.0M, cash $381.3M, inventories $802.5M, and a Vascular Intervention integration plan with $36–44M restructuring costs and expected annual savings of $24–30M.